{
    "pmcid": "10518403",
    "qa_pairs": {
        "How do VNARs enhance their therapeutic potential when fused with Fc domains?": [
            "By increasing their avidity and half-life, transforming them into bivalent or multivalent formats.",
            "By reducing their size and allowing better tissue penetration.",
            "By decreasing their immunogenicity and improving human compatibility.",
            "By enhancing their ability to bind to non-protein targets."
        ],
        "What is a major concern regarding the immunogenicity of VNARs?": [
            "Their evolutionary divergence from human antibodies.",
            "Their large size compared to human antibodies.",
            "Their inability to bind to human proteins.",
            "Their high similarity to human antibodies."
        ],
        "What is the preferred method for selecting VNARs against SARS-CoV-2?": [
            "Phage display technology.",
            "CRISPR-Cas9 screening.",
            "Yeast two-hybrid screening.",
            "Mass spectrometry analysis."
        ],
        "What type of interactions do VNARs often rely on for binding to the RBD of SARS-CoV-2?": [
            "Hydrophobic interactions.",
            "Ionic interactions.",
            "Covalent bonding.",
            "Van der Waals forces."
        ],
        "What unique structural feature do VNARs possess compared to other antibodies?": [
            "They lack the CDR2 loop and have two additional hypervariable regions (HV2 and HV4).",
            "They have an extra CDR2 loop and lack hypervariable regions.",
            "They possess three additional CDR loops instead of hypervariable regions.",
            "They have a unique CDR1 loop and no hypervariable regions."
        ]
    }
}